The U.S. Food and Drug Administration (FDA) approved Ozempic® as a treatment to reduce the risk of worsening chronic kidney disease (CKD) among adults with type 2 diabetes (T2D) and CKD. Ozempic (semaglutide) is an injected glucagon-like peptide-1 receptor agonist (GLP-1 RA). It has previously been approved as a treatment for adults with T2D to improve blood sugar control, and to reduce the risk of death from cardiovascular disease among adults with T2D and heart disease. Ozempic is manufactured by Novo Nordisk.

The FDA approval for this new indication based on the results of the FLOW . . .

Want To Read More? Log In Or Become A Free Member
Resource Available For All OPEN MINDS Circle Members
If you are already a member, log in to your account to access this resource and more.

You can become a free member and get access now. Learn more about the OPEN MINDS Circle Market Intelligence Service Membership. Reach out to our team at info@openminds.com, or call us at 877-350-6463.

A Paid OPEN MINDS Circle Membership provides unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!

Chronic Disease Management

The chronic disease management market encompasses consumers with chronic, complex conditions such as chronic kidney disease, diabetes, and heart disease. The challenges faced in this market are often compounded by the need for social services and supports. For provider organizations and health systems managing consumers with chronic conditions, a significant challenge that remains is addressing the rising cost of care for this population. As a result, payers are focusing on reducing the spend by increasing integrated models of care coordination across medical, behavioural, pharmacy, and social support systems. These new market forces are creating strategic opportunities for provider organizations that are serving this population.


There were 13.6 million people who were fully or partially dually eligible for Medicare and Medicaid for at least one month in 2022, according to a recent report conducted by two independent congressional agencies, the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission. Combined state and federal spending for dual eligibles totaled $548.8 billion in calendar year 2022. Medicare accounted for $351.4 billion (64%). About 38% of dual eligibles were… Read